The regulator said the buyout “would lead to a highly concentrated market for outsourced hydrophilic coatings and eliminate ...
Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale ...
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
Lake Street Capital upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a hold rating to a buy rating in a report published on Friday morning, Marketbeat.com reports. Lake Street Capital ...
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
WASHINGTON (Reuters) - The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' ...
Fintel on MSN1d
Lake Street Upgrades Surmodics (SRDX)Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback